by Peter Ciszewski | Jan 31, 2019
By Peter Ciszewski; January 3, 2019 Mitchell Cairo, MD, Chief of Pediatric Hematology, Oncology and Stem Cell Transplantation at New York Medical College discusses his study at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego. Sickle cell...
by Peter Ciszewski | Jan 30, 2019
The FDA approved ibrutinib for use in combination with obinutuzumab for treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. This is the first nonchemotherapy regimen indicated for this patient population. Ibrutinib...
by Peter Ciszewski | Jan 28, 2019
Alexion announced positive top line results in the Phase 3 study of Ultomiris (ravulizumab-cwvz), the long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS). In the initial...
by Peter Ciszewski | Jan 23, 2019
Excellent podcast on rare diseases. Rare disease affects 1 in 10 people and over 30 million people in the US. At times we feel like society defines us by the disease instead of who we are as a person. Join hosts and advocates Anne Bruns and Seth Rotberg as they...
by Peter Ciszewski | Jan 22, 2019
Ron Cooper, President and CEO of Albireo, provides and overview of Cholestatic liver diseases. Cholestasis is a chronic condition resulting from an impairment of the biliary system, that provokes a decrease or interruption of bile secretion from the liver to...
